These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 15961591)

  • 1. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination.
    Trotter CL; Gay NJ; Edmunds WJ
    Am J Epidemiol; 2005 Jul; 162(1):89-100. PubMed ID: 15961591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
    Trotter CL; Edmunds WJ
    Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States.
    Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE;
    Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carriage of Neisseria meningitidis in Europe: a review of studies undertaken in the region.
    Soriano-Gabarró M; Wolter J; Hogea C; Vyse A
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):761-74. PubMed ID: 21905785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006.
    Kinlin LM; Jamieson F; Brown EM; Brown S; Rawte P; Dolman S; Drews SJ; Fisman DN
    Vaccine; 2009 Mar; 27(11):1735-40. PubMed ID: 19186206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding prevention of invasive meningococcal disease.
    Pelton SI; Gilmet GP
    Expert Rev Vaccines; 2009 Jun; 8(6):717-27. PubMed ID: 19485753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae.
    Trotter CL; McVernon J; Ramsay ME; Whitney CG; Mulholland EK; Goldblatt D; Hombach J; Kieny MP;
    Vaccine; 2008 Aug; 26(35):4434-45. PubMed ID: 18617296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
    MacLennan J; Obaro S; Deeks J; Lake D; Elie C; Carlone G; Moxon ER; Greenwood B
    J Infect Dis; 2001 Jan; 183(1):97-104. PubMed ID: 11087205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines.
    Poland GA
    Clin Infect Dis; 2010 Mar; 50 Suppl 2():S45-53. PubMed ID: 20144016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Meningitis Vaccine Project.
    LaForce FM; Konde K; Viviani S; Préziosi MP
    Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neisseria meningitidis B vaccines.
    Panatto D; Amicizia D; Lai PL; Gasparini R
    Expert Rev Vaccines; 2011 Sep; 10(9):1337-51. PubMed ID: 21919622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.
    Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA
    Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Meningococcal disease in the Netherlands: media hype, but not an epidemic].
    van Furth AM; Zaaijer HL
    Ned Tijdschr Geneeskd; 2001 Sep; 145(36):1716-8. PubMed ID: 11572168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
    Soriano-Gabarró M; Rosenstein N; LaForce FM
    J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term protection in children with meningococcal C conjugate vaccination: lessons learned.
    Borrow R; Miller E
    Expert Rev Vaccines; 2006 Dec; 5(6):851-7. PubMed ID: 17184222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meningococcal C conjugate vaccine: the experience in England and Wales.
    Campbell H; Borrow R; Salisbury D; Miller E
    Vaccine; 2009 Jun; 27 Suppl 2():B20-9. PubMed ID: 19477053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quadrivalent meningococcal conjugate vaccines.
    Pace D; Pollard AJ; Messonier NE
    Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
    Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.